Press release
Monoclonal Antibody (mABs) Therapeutics Market worth $497.5 billion by 2029
Browse 365 market data Tables and 58 Figures spread through 350 Pages and in-depth TOC on "Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutane
Monoclonal Antibody (mABs) Therapeutics Market [https://www.marketsandmarkets.com/Market-Reports/monoclonal-antibody-mabs-therapeutics-market-115323820.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarkets Trademark . The monoclonal antibody therapeutics market is primarily driven by factors such as increasing prevalence of chronic diseases like cancer, autoimmune disorders, and infectious diseases. Technological advancements in antibody engineering and production processes also contribute significantly. Additionally, growing investments in research and development, coupled with expanding applications in personalized medicine, drive market growth. For example, drugs like rituximab (used for lymphoma and leukemia) and trastuzumab (used for breast cancer) exemplify the success and potential of monoclonal antibody therapeutics.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=115323820 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=115323820&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]
The In-Vitro accounted for the largest share of production method in the monoclonal antibody therapeutics market in 2023.
By Production Method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In-Vitro for the largest share of the monoclonal antibody therapeutics market in 2023. The in vitro production method for monoclonal antibody therapeutics is propelled by factors such as scalability, cost-effectiveness, and reduced risk of contamination compared to traditional in vivo methods. Advancements in cell culture technologies and bioprocessing techniques have enhanced productivity and consistency. Moreover, regulatory agencies favor in vitro production for its quality control advantages.
The human source segment is expected to grow at a higher rate during the forecast period.
Based on sources, monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human segment accounted for the largest share of the monoclonal antibody therapeutics market and humanized segment is expected to grow at a higher growth rate during the forecast period of 2024-2029. The human source monoclonal antibody therapeutics market is propelled by factors such as reduced immunogenicity, improved efficacy, and enhanced safety profiles compared to non-human sources. Increasing demand for precision medicine and personalized therapies also drives market growth. Technological advancements in antibody discovery platforms, such as phage display and transgenic mice, further accelerate development timelines. Examples include adalimumab (Humira) for autoimmune diseases and pembrolizumab (Keytruda) for cancer, highlighting the success and potential of human-sourced monoclonal antibody therapeutics in addressing diverse medical needs.
The autoimmune and inflammatory segment accounted for the largest share of the therapy area segment in the monoclonal antibody therapeutics market in 2023.
Based on therapy area the monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, oncology, hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases segment dominated the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for autoimmune and inflammatory diseases and cancer is driven by several factors. For autoimmune and inflammatory diseases, increasing prevalence, unmet medical needs, and advancements in targeted therapies propel market growth. Examples include adalimumab (Humira) for rheumatoid arthritis and infliximab (Remicade) for Crohn's disease. In cancer, rising incidence rates, expanding treatment options, and personalized medicine approaches contribute to market expansion.
The hospitals accounted for the largest share of end user in the monoclonal antibody therapeutics market in 2023.
By end user, hospitals, long-term care facilities, and other end users. In 2023, hospitals accounted for the largest share of the monoclonal antibody therapeutics market. The monoclonal antibody therapeutics market for hospitals is driven by factors such as increasing patient admissions, advancements in healthcare infrastructure, and growing demand for advanced treatments. Examples include hospitals incorporating monoclonal antibody therapies like bevacizumab (Avastin) for cancer into their treatment regimens, enhancing patient care and outcomes
Europe is likely to grow at significant CAGR during forecast period of 2024-2029.
The monoclonal antibody therapeutics market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. North America dominated the monoclonal antibody therapeutics market. Europe's accelerated growth is attributed to several factors. Robust healthcare infrastructure, favorable government policies, increased research and development investments, rising prevalence of chronic diseases, and expanding adoption of innovative medical technologies. Additionally, collaborations between academia, industry, and regulatory bodies further drive advancements in healthcare, propelling Europe towards faster-paced growth in various medical sectors.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=115323820 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=115323820&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]
Monoclonal Antibody (mABs) Therapeutics Market Dynamics:
Drivers:
* Advancements in biotechnology and genetic engineering
* Increasing demand for personalized medicine
* Growing product pipeline of mAb therapeutics
Restraints:
* Stringent regulatory approval process
* High cost of mAb treatments
Opportunities:
* Innovative therapeutic indications
* Rising technological advancements in antibody engineering
Challenge:
* Rising development & production costs
Key Market Players of Monoclonal Antibody (mABs) Therapeutics Industry:
Key players in the monoclonal antibody therapeutics market are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), Regeneron Pharmaceuticals Inc. (US), and among others.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=115323820 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=115323820&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=monoclonal-antibody-mabs-therapeutics-market-worth-4975-billion-by-2029]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Monoclonal Antibody (mABs) Therapeutics Market worth $497.5 billion by 2029 here
News-ID: 3460897 • Views: …
More Releases from ABNewswire
Rhino Rescue's Quality Pledge: Unveiling the Extreme Resilience of Core Componen …
Discover Rhino Rescue's quality pledge through our extreme component testing. See why our tactical gear is built to perform.
Our Commitment and Responsibility
In the life and death arena of emergency response, where seconds matter, the dependability of your equipment is absolute. It is a fact that has been guiding our mission since our parent company, Nanchi Medical, was established in 2010. Having a 14-year history in the first aid industry and…
Tampa SEO Launches Cutting-Edge Local Search Optimization Services to Help Tampa …
Tampa SEO, a full-service digital marketing agency based in Tampa Bay, today announced the official launch of its enhanced SEO and digital marketing services at http://tampa-seo.net. The company specializes in helping local businesses increase their online visibility, generate qualified leads, and outperform competitors through data-driven, ethical search engine optimization strategies.
Helping Local Businesses Thrive in the Digital Age
With nearly 97% of consumers searching online for local services before making a purchase,…
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveIn …
The Key Fibromyalgia Companies in the market include - Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial - Portela C S.A, and others.
DelveInsight's "Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States,…
DMB Plumbing & Heating Urges Homeowners to Schedule Pre-Winter Heating Inspectio …
DMB Plumbing & Heating Inc. of Bridgewater, led by Dean Blanchard, is urging homeowners to schedule pre-winter heating inspections.
As temperatures in Massachusetts begin to dip and residents prepare their homes for another New England winter, DMB Plumbing & Heating Inc., a locally owned and operated company based in Bridgewater, is reminding homeowners of the importance of pre-winter heating inspections.
Founded and operated by Dean Blanchard, DMB Plumbing & Heating has long…
More Releases for Monoclonal
Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Monoc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Monoclonal Antibodies (MAbs) Market Through 2025?
The market for monoclonal antibodies (MAbs) has experienced swift expansion in the recent past. The market value is projected to rise from $234.37 billion in 2024 to $261.66 billion in 2025, exhibiting a compound annual growth…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The arthritis monoclonal antibodies…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Monoclonal Antibody Therapy Market - Empowering the immune system: Monoclonal an …
Newark, New Castle, USA: The "Monoclonal Antibody Therapy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Monoclonal Antibody Therapy Market: https://www.growthplusreports.com/report/monoclonal-antibody-therapy-market/7736
This latest report researches the industry structure,…
